PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases.
Based on the Company’s core proprietary ‘Protein Interference’ technology’, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.
In the media
6th December 2018
Abcam deputy chairman Jonathan Milner buys 06 December 2018
He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Definigen Limited and CamAllergy Ltd. Jonathan holds an Executive Director position at Meltwind Limited,
29th November 2018
Cambridge investments a walk in the park for Parkwalk
3D Touch is an enhanced user interface which is now being deployed by all leading mobile and smart device makers. PhoreMost, a biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets,
31st October 2018
Head Line: European Patent Office granted patent to PHOREMOST LTDâ€‚[GB] titled as "METHODS OF SCREENING"
EP3394621 on October 31, 2018, to PHOREMOST LTDâ€‚[GB] titled as "METHODS OF SCREENING"Inventor(s): HARDWICK BRYN SHAUNâ€‚[GB]; MCKENZIE GRAHAME JAMESâ€‚[GB] + (HARDWICK, Bryn Shaun, ;